Skip to main content
SpringerLink
Log in

The evolution of primary chemotherapy in breast cancer treatment

  • Review Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Primary chemotherapy may be thought of as having evolved over three generations. First-generation primary chemotherapy followed trials which proved that the prognosis of breast cancer patients receiving primary chemotherapy was the same as that of patients receiving post-operative chemotherapy. Second-generation primary chemotherapy followed trials which demonstrated that regimens containing anthracy-clines and taxanes yielded complete pathological response rates (pCR) of over 20%. Third-generation primary chemotherapy followed trials which demonstrated that inclusion of newer agents, such as trastuzumab and capetitabine, in combination with taxanes could yield pathological CR rates of over 30%. In third-generation primary chemotherapy, predictive factors, especially those analyzed by DNA array analysis, play a key role. Other issues, including the relevance of sentinel node biopsy after primary chemotherapy and the importance of marking the site of the primary tumor before primary chemotherapy in cases showing cCR, are highlighted. This article deals with the history of the evolution of primary chemotherapy, along with a discussion of some relevant issues.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Goldie JH, Coldman AJ: A mathematical model for relating the drug sensitivity of tumors to their sponta neous mutation rate.Cancer Treat Rep 63:1727–1733, 1979.

    PubMed  CAS  Google Scholar 

  2. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilhuydy JM, Bonichon F: Neoad-juvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS).Ann Oncol 10:47–52, 1999.

    Article  PubMed  CAS  Google Scholar 

  3. Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, Nash AG, Ford HT: A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer.Ann Oncol 9:1179–1184,1998.

    Article  PubMed  CAS  Google Scholar 

  4. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol 16:2672–2685, 1998.

    PubMed  CAS  Google Scholar 

  5. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangie T, Jouve M, Beuze-boc P, Garcio-Giralt E, Salmon RJ de la Rochefordiere A, Campana F, Pouillart P: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6Eur J Cancer 30A:645–652,1994.

    Article  PubMed  CAS  Google Scholar 

  6. Jakesz R: Comparison of pre-vs. postoperative chemotherapy in breast cancer patients: Four-year results of Austrian Breast & Colorectal Study Group (ABCSG) Trial 7.Proc Am Soc Clin Oncol #125, 2001.

  7. Ikeda T, Jinno H, Matsui A, Masamura S, Kitajima M: The role of neoadjuvant chemotherapy for breast cancer treatment.Breast Cancer 9:8–14, 2002.

    Article  PubMed  Google Scholar 

  8. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault R, Carter C, Singletary SE, Kuerer H, Hunt K, Strom E, Hortobagyi GN: Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC-Final results of a prospective phase HI randomized trial.Proc Am Soc Clin Oncol #135,2002.

  9. Ezzat AA, Ibrahim EM, Ajarim DS, Rahal MM, Raja MA, Stuart RK, Tulbah AM, Kandil A, Al-Malik OA, Bazarbashi SM: High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin.Breast Cancer Res Treat 62:237–244, 2000.

    Article  PubMed  CAS  Google Scholar 

  10. Luporsi E, Vanlemmens L, Coudert B, Mayer F, Bonneterre J, Petit T, Borel C, Hirsch M, Bey P: 6 cycles of FEC 100 vs 6 cycles of Epirubicin-Docetaxel (ED) as neoadjuvant chemotherapy in operable breast cancer patients (Pts) : Preliminary results of a randomized phase II trial of Girec S01.Proc Am Soc Clin Oncol #355,2000.

  11. Tubiana-Hulin M, Dieras V, Fumoleau P, Combe M, Misset J-L, Vannetzel J-M, Bachelot T, Boccara Ch, Ganem G: Phase II trial combining Docetaxel (D) Doxorubicine (DOX) as neo adjuvant treatment in patients (Pts) with operable breast carcinoma (BC).Proc Am Soc Clin Oncol #495, 2000.

  12. Lara F, De la Garza J, Ramirez T: High pathological complete response (pCR) after neoadjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer.Proc Am Soc Clin Oncol #492,2000.

  13. Burstein HJ, Harris LN, Kaelin CM, Christian RL, Parker LM, Gelman R, Ellisen LW, Kuter I, Gadd MA, Kennedy PR, Borges V, Bunnell CA, Tribou L, Younger J, Smith BL, Winer EP: Preoperative Her-ceptin and Paxlitaxel (Taxol) for HER2 overexpressing (HER2+) Stage II/III breast cancer.Proc Am Soc Clin Oncol #100, 2001.

  14. von Minckwitz G, Raab G, Schutte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe D, Jackisch C, duBois A, Caputo A, Kaufmann M: Dose-dense versus seqential adriamycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2, MO)-Primary endpoint analysis of the GEPAR-DUO study.Proc Am Soc Clin Oncol #168,2003.

  15. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N; National Surgical Adjuvant Breast and Bowel Project Protocol B-27.: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.J Clin Oncol 21:4165–4174,2003.

    Article  PubMed  CAS  Google Scholar 

  16. Davidson NE, Kennedy JK, and Armstrong DK: Dose-intensive chemotherapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds Diseases of the breast, second ed, Lippinncott Williams & Wilkins, Philadelphia, pp633–644, 2000.

    Google Scholar 

  17. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM: Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.N Engl J Med 349:17–26,2003.

    Article  PubMed  CAS  Google Scholar 

  18. Stadtmauer EA, O’Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH: Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.N Engl J Med 342:1069–1076,2000.

    Article  PubMed  CAS  Google Scholar 

  19. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE: Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.J Natl Cancer Inst 92:1271–1272,2000.

    Article  Google Scholar 

  20. Citron ML, Berry D, Cirrincione C, Carpenter J, Hudis C, Gradishar W, Davidson N, Ingle J, Martino S, Livingston R, Winer E, Muss H, Norton L: Superiority of dose-dense over conventional scheduling and equivalence ofsequential vs. combination adjuvant chemotherapy for node-positive breast cancer (CALGB9741, INTC9741), Proceedings for 25th SABCS#, 2002.

  21. Tubiana-Hulin M, Romieu G, Fumoleau P, Namer M, Delva R, Guastalla JP, Lotz JP, Kerbrat P, Pujade-Lau-raine E, Eichler F, Dohollou N, MacGrogan G, Quin-aux E, Grau B: A randomized, parallel study of 4 or 6 Cycles of Adramycin/Taxol (paclitaxel) (AT) as neoadjuvant treatment of breast cancer. (BC).Proc Am Soc Clin Oncol #1879, 2001.

  22. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton P, and Ogston KN: Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel.J Clin Oncol 20:1456–1466,2002.

    Article  PubMed  CAS  Google Scholar 

  23. von Minckwitz G, Raab G, Blohmer JU, Gerber B, Loehr A, Costa SD, Eidtmann H, Hilfrich J, Jackisch C, Kaufmann M: Primary chemotherapy adapted on in-vivo chemosensitivity in patients with primary breast cancer. The pilot GEPARTRIO-study.Proc Am Soc Clin Oncol #85,2003.

  24. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med 344:783–792,2001.

    Article  PubMed  CAS  Google Scholar 

  25. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP: Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.J Clin Oncol 21:46–53, 2003.

    Article  PubMed  CAS  Google Scholar 

  26. Hurley J, Doliny P, Silva O, Gomez-Fernandez C, Reis I, Velez P, Castillo M, Bateman D, Franco S, Gautam U: Neoadjuvant herceptin/taxotere/cisplatin in the treatment of locally advanced and inflammatory breast cancer.Proc Am Soc Clin Oncol #196, 2002.

  27. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B: Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.Cancer 92:1759–1768,2001.

    Article  PubMed  CAS  Google Scholar 

  28. Welt A, Von Minckwitz G, Borquez D, Oberhoff C, Kaufmann M, Seeber S, Vanhoefer U: Extended phaseI study of capecitabine in combination with vinorelbine in pretreated patients with metastatic breast cancer. Proceedings for SABCS #336,2002.

  29. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pre-treated patients with advanced breast cancer: phase I trial results.J Clin Oncol 20:2812–2823, 2002.

    Article  PubMed  CAS  Google Scholar 

  30. O’Shaughnessy J: The evolving role of capecitabine in breast cancer.Clin Breast Cancer 4:S20–25,2003.

    Article  PubMed  CAS  Google Scholar 

  31. Personal communication

  32. I keda T, Jinno H, Kitajima M, Shirane M, Tajima G, Suto A: Chemo sensitivity-related genes of breast cancer detected by DNA microarray.Proc Am Soc Clin Oncol #34,2003.

  33. Pusztai L, Ayers M, Simmans FW, Damokosh A, Hess K, Valero V, Clark E, Ross J, Hortobagyi GN: Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer.Proc Am Soc Clin Oncol #1,2003.

  34. Nason KS, Anderson BO, Byrd DR, Dunnwald LK, Eary JF, Mankoff DA, Livingston R, Schmidt RA, Jewell KD, Yeung RS, Moe RE: Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma.Cancer 89:2187–2194,2000.

    Article  PubMed  CAS  Google Scholar 

  35. Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, Delpassand ES, House R, Ames FC, Feig BW, Ross MI, Singletary SE, Buzdar AU, Hortobagyi GN, Hunt KK: Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.J Clin Oncol 18:3480–3486,2000.

    PubMed  CAS  Google Scholar 

  36. Cohen LF, Breslin TM, Kuerer HM, Ross MI, Hunt KK, Sahin AA Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy.Am J Surg Pathol 24:1266–1272,2000.

    Article  PubMed  CAS  Google Scholar 

  37. Miller AR, Thomason VE, Yeh IT, Alrahwan A, Sharkey FE, Stauffer J, Otto PM, McKay C, Kahlen-berg MS, Phillips WT, Cruz AB Jr: Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma.Ann Surg Oncol 9:243–247, 2002.

    Article  PubMed  Google Scholar 

  38. Sterns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN: Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast caner.Ann Surg Oncol 9:235–242,2002.

    Article  Google Scholar 

  39. Brady EW: Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer.Breast J 8:97–100,2002.

    Article  PubMed  Google Scholar 

  40. Julien TB, Dusi D, Wolmark N: Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer.Am J Surg 184:315–317, 2002.

    Article  Google Scholar 

  41. Reitsamer R, Peintinger F, Rettenbacher L, Prokop E: Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.J Surg Oncol 84:63–67,2003.

    Article  PubMed  Google Scholar 

  42. Schwartz GF, Meltzer AJ: Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma for carcinoma of the breast.Breast J 9:374–379, 2003.

    Article  PubMed  Google Scholar 

  43. Piato JR, Barros AC, Pincerato KM, Sampaio AP, Pinotti JA: Sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy.Eur J Surg Oncol 29:118–120, 2003.

    Article  PubMed  Google Scholar 

  44. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuze-boc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T, Senn HJ: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.J Clin Oncol 21:2600–2608, 2003.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan

    Tadashi Ikeda, Hiromitsu Jinno & Masaki Kitajima

Authors
  1. Tadashi Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiromitsu Jinno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masaki Kitajima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadashi Ikeda.

About this article

Cite this article

Ikeda, T., Jinno, H. & Kitajima, M. The evolution of primary chemotherapy in breast cancer treatment. Breast Cancer 11, 148–155 (2004). https://doi.org/10.1007/BF02968294

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02968294

Key words

Search

Navigation